August 10, 2021 11:15 AM EDTUpdated February 28, 07:38 AM

Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for

Zachary Brennan

Senior Editor

Tracker updated on 2/28/25 to note that Zevra Therapeutics sold its PRV for the approval of Miplyffa for $150 million. Vertex also recently used one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot

Kennedy announces 10,000 job cuts at HHS, with major reductions expected at FDA, NIH and CDC

Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

Small biotech joins list of health com­pa­nies tak­ing a trip to Trump's Mar-a-La­go

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

No­vo Nordisk pays $200M up­front for Chi­na-based biotech’s triple-G obe­si­ty shot

Kennedy an­nounces 10,000 job cuts at HHS, with ma­jor re­duc­tions ex­pect­ed at FDA, NIH and CDC

Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot

Kennedy announces 10,000 job cuts at HHS, with major reductions expected at FDA, NIH and CDC